by Ricky Zipp After a three-year IPO drought, the industry is questioning whether the window for medtech public offerings is open...

By James Thorne After three years in the IPO desert, VCs look parched. The asset class recorded just $149 billion in exit value in the US...

By Sean Whooley Boston Scientific trial misses endpoint Edwards has positive data for Evoque, early TAVR Inari Medical touts FlowTriever...